Annual report
7317.TEDINET S100YI6P
Period2025-04-01 → 2026-03-31
Filed2026-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥9.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.6bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.1bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥675m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥409m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥953m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥426m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥165m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥12.5bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥10.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.9bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.7bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.9bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.4bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.0bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.1bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.2bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.4bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.9bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.5bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥528m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥915m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥140m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥746m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥616m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥485m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥284m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥38m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥183m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥504m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥72.5 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.38 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.03 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.17 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.85 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.9 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥72.55 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.43 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.02 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.75 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥380.42 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥324.88 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥244.72 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥178.69 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥153.44 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 65.2% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.2% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 20.6% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 25.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,552 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,403 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,367 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,383 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 1,442 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥3.8bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥3.3bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥3.2bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | −¥93m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥149m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥472m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥903m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥347m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥68m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥31m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥311m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥637m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥305m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥636m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥206m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥320m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥4m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥4.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥4.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.1bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.2bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.9bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.3bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥14.27 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.89 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.74 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-15.16 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.2 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥14.15 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.55 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥9.61 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥10 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥2.5 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥90.01 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥85.11 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥56.75 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥47.4 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥63.58 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 37.3% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.5% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.3% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 42.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.7% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.3% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,427,600 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,342,800 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,223,200 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,281,800 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,275,400 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 46 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 43 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 39 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 39 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-04-01 → 2026-03-31 | ¥102m |
| Otherother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥102m |
| Otherother segments | segment assets | at 2026-03-31 | ¥7m |
| Otherother segments | segment profit | 2025-04-01 → 2026-03-31 | −¥35m |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥367m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥10m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥356m |
| Medical Healthcarereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥384m |
| Medical Healthcarereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥96m |
| Medical Healthcarereportable segment | employees | at 2026-03-31 | 583 pure |
| Medical Healthcarereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥6.8bn |
| Medical Healthcarereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥6.8bn |
| Medical Healthcarereportable segment | segment assets | at 2026-03-31 | ¥5.5bn |
| Medical Healthcarereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.1bn |
| Safety Systemreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥162m |
| Safety Systemreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥80m |
| Safety Systemreportable segment | employees | at 2026-03-31 | 960 pure |
| Safety Systemreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.9bn |
| Safety Systemreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.9bn |
| Safety Systemreportable segment | segment assets | at 2026-03-31 | ¥5.0bn |
| Safety Systemreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥397m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥546m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥176m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥2.5bn |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥129m |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥129m |
| Otherother segments | segment assets | at 2025-03-31 | ¥55m |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥31m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥18m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥318m |
| Medical Healthcarereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥193m |
| Medical Healthcarereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥83m |
| Medical Healthcarereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Medical Healthcarereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Medical Healthcarereportable segment | segment assets | at 2025-03-31 | ¥4.8bn |
| Medical Healthcarereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Safety Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥319m |
| Safety Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥106m |
| Safety Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Safety Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Safety Systemreportable segment | segment assets | at 2025-03-31 | ¥4.1bn |
| Safety Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥253m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥512m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥189m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥9.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Medical Healthcarereportable segment | employees | at 2026-03-31 | 13 pure |
| Safety Systemreportable segment | employees | at 2026-03-31 | 24 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,407
| Item | Context | Value | Unit |
|---|---|---|---|
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E35560-000UrushimaKeigoMember | Original text (Japanese)（注）３ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding accumulated depreciation of property plant and equipment (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amounts of reduction entry of property plant and equipment (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding provision for loss on order received included in cost of sales (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding transactions with affiliated entities (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding provision for directors retirement rewards (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on disposal of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments income taxes and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |